Article

Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial

2023-05-10

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold> Neoadjuvant chemotherapy (NACT) is the mainstay of treatment of stages II and III triple-negative breast cancer (TNBC). There is interest in the addition of carboplatin to NACT, especially in TNBC patients with germline BRCA mutations or other genomic alterations associated with DNA repair deficiency. This study aims to evaluate if the addition of carboplatin to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5063c2a0-4f00-560e-acc3-158faba9239d
DOI: 10.21203/rs.3.rs-2874299/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trialDOI 10.21203/rs.3.rs-2874299/v1Read

The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancerSemantic proximity Read

BRCA1/2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisSemantic proximity Read

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer - one clinic experience.Semantic proximity Read

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast CancerSemantic proximity Read

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).Semantic proximity Read

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.Semantic proximity Read

Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.Semantic proximity Read

The Impact of Germline BRCA Mutations in Locally Advanced, Triple Negative Breast Cancer Treated with Platinum Based Neoadjuvant ChemotherapySemantic proximity Read

Neoadjuvant Chemotherapy in early-stage breast cancer: the trend over time and the impact on axillary management, A National Cancer Database AnalysisSemantic proximity Read

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancerSemantic proximity Read

Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer.Semantic proximity Read

Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple Negative Breast CancerSemantic proximity Read